S&P 500   3,850.05 (-1.92%)
DOW   31,528.31 (-1.36%)
QQQ   315.78 (-2.58%)
AAPL   122.47 (-2.30%)
MSFT   231.06 (-1.49%)
FB   257.60 (-2.54%)
GOOGL   2,026.01 (-2.77%)
AMZN   3,085.71 (-2.34%)
TSLA   696.09 (-6.19%)
NVDA   537.49 (-7.32%)
BABA   243.60 (-2.69%)
CGC   33.79 (-5.08%)
GE   12.85 (-2.06%)
MU   89.81 (-2.93%)
NIO   47.77 (-7.89%)
AMD   83.06 (-4.46%)
T   28.72 (-2.25%)
F   11.90 (-3.02%)
ACB   11.05 (-5.07%)
DIS   193.25 (-2.16%)
BA   219.99 (-4.08%)
NFLX   540.86 (-2.27%)
BAC   36.18 (-0.55%)
S&P 500   3,850.05 (-1.92%)
DOW   31,528.31 (-1.36%)
QQQ   315.78 (-2.58%)
AAPL   122.47 (-2.30%)
MSFT   231.06 (-1.49%)
FB   257.60 (-2.54%)
GOOGL   2,026.01 (-2.77%)
AMZN   3,085.71 (-2.34%)
TSLA   696.09 (-6.19%)
NVDA   537.49 (-7.32%)
BABA   243.60 (-2.69%)
CGC   33.79 (-5.08%)
GE   12.85 (-2.06%)
MU   89.81 (-2.93%)
NIO   47.77 (-7.89%)
AMD   83.06 (-4.46%)
T   28.72 (-2.25%)
F   11.90 (-3.02%)
ACB   11.05 (-5.07%)
DIS   193.25 (-2.16%)
BA   219.99 (-4.08%)
NFLX   540.86 (-2.27%)
BAC   36.18 (-0.55%)
S&P 500   3,850.05 (-1.92%)
DOW   31,528.31 (-1.36%)
QQQ   315.78 (-2.58%)
AAPL   122.47 (-2.30%)
MSFT   231.06 (-1.49%)
FB   257.60 (-2.54%)
GOOGL   2,026.01 (-2.77%)
AMZN   3,085.71 (-2.34%)
TSLA   696.09 (-6.19%)
NVDA   537.49 (-7.32%)
BABA   243.60 (-2.69%)
CGC   33.79 (-5.08%)
GE   12.85 (-2.06%)
MU   89.81 (-2.93%)
NIO   47.77 (-7.89%)
AMD   83.06 (-4.46%)
T   28.72 (-2.25%)
F   11.90 (-3.02%)
ACB   11.05 (-5.07%)
DIS   193.25 (-2.16%)
BA   219.99 (-4.08%)
NFLX   540.86 (-2.27%)
BAC   36.18 (-0.55%)
S&P 500   3,850.05 (-1.92%)
DOW   31,528.31 (-1.36%)
QQQ   315.78 (-2.58%)
AAPL   122.47 (-2.30%)
MSFT   231.06 (-1.49%)
FB   257.60 (-2.54%)
GOOGL   2,026.01 (-2.77%)
AMZN   3,085.71 (-2.34%)
TSLA   696.09 (-6.19%)
NVDA   537.49 (-7.32%)
BABA   243.60 (-2.69%)
CGC   33.79 (-5.08%)
GE   12.85 (-2.06%)
MU   89.81 (-2.93%)
NIO   47.77 (-7.89%)
AMD   83.06 (-4.46%)
T   28.72 (-2.25%)
F   11.90 (-3.02%)
ACB   11.05 (-5.07%)
DIS   193.25 (-2.16%)
BA   219.99 (-4.08%)
NFLX   540.86 (-2.27%)
BAC   36.18 (-0.55%)
Log in
NASDAQ:ADMP

Adamis Pharmaceuticals News Headlines

$1.18
-0.06 (-4.84 %)
(As of 02/25/2021 02:29 PM ET)
Add
Compare
Today's Range
$1.12
Now: $1.18
$1.22
50-Day Range
$0.66
MA: $1.21
$1.79
52-Week Range
$0.27
Now: $1.18
$2.34
Volume187,961 shs
Average Volume30.55 million shs
Market Capitalization$158.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68

Headlines

Adamis Pharmaceuticals (NASDAQ ADMP) News Headlines Today

Source:
SourceHeadline
Adamis Pharmaceuticals (NASDAQ:ADMP) Lowered to Sell at Zacks Investment ResearchAdamis Pharmaceuticals (NASDAQ:ADMP) Lowered to Sell at Zacks Investment Research
marketbeat.com - February 15 at 3:37 PM
Adamis gets FDA greenlight for tempol human studies in COVID-19Adamis gets FDA greenlight for tempol human studies in COVID-19
seekingalpha.com - February 24 at 12:31 PM
Adamis Pharmaceuticals (NASDAQ:ADMP) Shares Gap Down to $1.35Adamis Pharmaceuticals (NASDAQ:ADMP) Shares Gap Down to $1.35
americanbankingnews.com - February 23 at 11:31 AM
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
finance.yahoo.com - February 22 at 11:49 AM
Adamis Pharmaceuticals Says Received Notice That One Patent Application Relating To ZIMHI Was Allowed By U.S. Patent And Trademark OfficeAdamis Pharmaceuticals Says Received Notice That One Patent Application Relating To ZIMHI Was Allowed By U.S. Patent And Trademark Office
benzinga.com - February 19 at 11:26 PM
Adamis Pharmaceuticals (NASDAQ:ADMP) Stock Price Down 5.1%Adamis Pharmaceuticals (NASDAQ:ADMP) Stock Price Down 5.1%
americanbankingnews.com - February 17 at 7:28 PM
Adamis Pharma Shares Fall Despite US Patent Covering NaloxoneAdamis Pharma Shares Fall Despite US Patent Covering Naloxone
finance.yahoo.com - February 17 at 5:24 PM
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product CandidateAdamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
finance.yahoo.com - February 17 at 12:24 PM
Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Sees Significant Increase in Short InterestAdamis Pharmaceuticals Co. (NASDAQ:ADMP) Sees Significant Increase in Short Interest
americanbankingnews.com - February 14 at 2:28 AM
Adamis Pharmaceuticals (NASDAQ:ADMP) Trading Up 7%Adamis Pharmaceuticals (NASDAQ:ADMP) Trading Up 7%
americanbankingnews.com - February 5 at 7:30 PM
Adamis Pharmaceuticals Announces Closing of Public Offering of Common StockAdamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - February 2 at 5:43 PM
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 PatientsAdamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
finance.yahoo.com - January 28 at 10:00 AM
Adamis Pharmaceuticals Provides Update On Its US Compounding BusinessAdamis Pharmaceuticals Provides Update On Its US Compounding Business
finance.yahoo.com - January 26 at 9:20 AM
Adamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: AnalystAdamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: Analyst
finance.yahoo.com - January 21 at 9:28 PM
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares SoarAdamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
finance.yahoo.com - January 21 at 4:28 PM
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine ProductsSYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
finance.yahoo.com - January 21 at 4:28 PM
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
finance.yahoo.com - January 20 at 3:08 PM
Adamis Soars After Submitting Covid Drug to FDAAdamis Soars After Submitting Covid Drug to FDA
finance.yahoo.com - January 20 at 3:08 PM
Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% HigherAdamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% Higher
finance.yahoo.com - January 8 at 1:16 PM
ADMP Dec 2020 2.500 callADMP Dec 2020 2.500 call
finance.yahoo.com - December 19 at 11:26 PM
Adamis Pharmaceuticals CorpAdamis Pharmaceuticals Corp
bloomberg.com - December 18 at 12:39 AM
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response LetterAdamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
finance.yahoo.com - December 1 at 5:41 PM
ADMP Snubbed Again, FDA Delays Decision On BMYs Liso-cel, MRNAs COVID-19 Vaccine 94.5% EffectiveADMP Snubbed Again, FDA Delay's Decision On BMY's Liso-cel, MRNA's COVID-19 Vaccine 94.5% Effective
nasdaq.com - November 17 at 7:42 AM
Why Adamis Pharmaceuticals Stock Is Trading Lower TodayWhy Adamis Pharmaceuticals Stock Is Trading Lower Today
finance.yahoo.com - November 16 at 3:10 PM
Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdoseAdamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose
seekingalpha.com - November 16 at 10:10 AM
Adamis Pharma Q3 top line down 27% on drop in elective surgeriesAdamis Pharma Q3 top line down 27% on drop in elective surgeries
seekingalpha.com - November 12 at 12:39 AM
Adamis Pharmaceuticals -4% as Q3 revenue negatively impacted by reductions of elective surgeriesAdamis Pharmaceuticals -4% as Q3 revenue negatively impacted by reductions of elective surgeries
seekingalpha.com - November 10 at 2:16 PM
Adamis Pharmaceuticals Corporations (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call TranscriptAdamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 9 at 11:04 PM
Adamis Pharmaceuticals: Q3 Earnings InsightsAdamis Pharmaceuticals: Q3 Earnings Insights
benzinga.com - November 9 at 6:03 PM
Adamis Pharmaceuticals EPS misses by $0.01, misses on revenueAdamis Pharmaceuticals EPS misses by $0.01, misses on revenue
seekingalpha.com - November 9 at 6:03 PM
Adamis Pharmaceuticals Corp. to Host Earnings CallAdamis Pharmaceuticals Corp. to Host Earnings Call
finance.yahoo.com - November 9 at 6:03 PM
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business UpdateAdamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
finance.yahoo.com - November 9 at 6:03 PM
Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business UpdateAdamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
finance.yahoo.com - November 5 at 9:27 AM
Looking Into Adamis Pharmaceuticalss Return On Capital EmployedLooking Into Adamis Pharmaceuticals's Return On Capital Employed
benzinga.com - October 12 at 5:16 PM
Adamis Pharmaceuticals prices equity offering, shares down 13%Adamis Pharmaceuticals prices equity offering, shares down 13%
seekingalpha.com - September 18 at 11:39 AM
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common StockAdamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 18 at 11:38 AM
Adamis Pharmaceuticals under pressure after public offeringAdamis Pharmaceuticals under pressure after public offering
seekingalpha.com - September 17 at 7:39 PM
Adamis Pharmaceuticals to launch a public offering of stockAdamis Pharmaceuticals to launch a public offering of stock
seekingalpha.com - September 17 at 7:39 PM
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and ProposalsAdamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals
finance.yahoo.com - August 25 at 12:32 PM
Adamis Pharmaceuticals Provides Update on Annual Meeting of StockholdersAdamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
finance.yahoo.com - August 21 at 1:31 PM
Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call TranscriptAdamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 20 at 10:29 PM
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business UpdateAdamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
finance.yahoo.com - August 17 at 6:41 PM
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue EstimatesAdamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 17 at 6:41 PM
Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19
finance.yahoo.com - August 14 at 1:43 PM
Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price RequirementAdamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
finance.yahoo.com - August 5 at 4:15 PM
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
finance.yahoo.com - July 23 at 1:25 PM
Adamis Pharmaceuticals Provides Update on SYMJEPI ProductsAdamis Pharmaceuticals Provides Update on SYMJEPI Products
finance.yahoo.com - July 1 at 1:03 PM
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdoseAdamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
finance.yahoo.com - June 18 at 9:43 AM
BRIEF-Adamis Pharmaceuticals Announces License To Commercialize TempolBRIEF-Adamis Pharmaceuticals Announces License To Commercialize Tempol
www.reuters.com - June 15 at 1:34 PM
Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?
www.marketwatch.com - June 15 at 1:34 PM
Adamis in-licenses drug for potential treatment of COVID-19Adamis in-licenses drug for potential treatment of COVID-19
seekingalpha.com - June 15 at 1:34 PM
This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.